ArticleExpert opinion on therapeutic targets2011
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
Article in Expert opinion on therapeutic targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 159 citations in OpenAlex.
- Article
- Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.PloS one · 2021Article
- Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique.Thoracic cancer · 2020Article
- Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.Translational cancer research · 2019Article
- NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines.Cancer research and treatment · 2019Article
- Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Efficacy of crizotinib inJournal of thoracic disease · 2016Article
- The expression ofJournal of thoracic disease · 2016Article
- Alectinib-a new chapter in the management of ALK-positive lung cancer.Translational lung cancer research · 2016Article
- Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Neuro-oncology · 2015Article
- Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.Journal of thoracic disease · 2015Article
- Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.International journal of clinical and experimental pathology · 2015Article
- Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.Journal of experimental & clinical cancer research : CR · 2014Article
- Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.Cancer research · 2014Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn lung adenocarcinoma, certain mutations such as echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower sensitivity to chemotherapy, when used conventionally as the first-line therapy in the advanced stage of the disease. AREAS COVERED: This paper discusses the clinical and therapeutic importance of ALK mutations in NSCLC and the early clinical results of a Phase I study assessing crizotinib in patients with ALK mutations. EXPERT OPINION: Abnormal ALK is evolving as an important therapeutic target in patients with more aggressive lung adenocarcinoma. Further clinical studies are needed in order to assess if crizotinib, an ALK inhibitor, is able to increase the efficacy of the conventional chemotherapy in this disease subset.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.